Research programme: ROR gamma antagonists - Orca Pharmaceuticals

Drug Profile

Research programme: ROR gamma antagonists - Orca Pharmaceuticals

Alternative Names: Autoimmune disorder therapeutics - Orca Pharmaceuticasl; BBI-6000; ROR gamma antagonists; ROR gammat inhibitors; RORγt inhibitors

Latest Information Update: 28 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator New York University
  • Developer New York University; Orca Pharmaceuticals; University of Oxford
  • Class Small molecules
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders

Most Recent Events

  • 24 Nov 2015 Brickell has the exclusive world-wide rights to a series of novel retinoic acid-related orphan nuclear receptor gamma (RORγ) inhibitors from Orca Pharmaceuticals
  • 01 Apr 2014 Preclinical trials in Autoimmune disorders in United Kingdom (PO)
  • 01 Sep 2013 Preclinical trials in Autoimmune disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top